News 15.09.2022 Schlieren (Zurich), Switzerland, September 15, 2022 – Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the...
News 08.09.2022 Zurich-Schlieren, Switzerland, September 08, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, announces grant of patent in China for Proclarix®. The China National Intellectual Property Administration notified Proteomedix of the grant of the patent for the invention described in the application No. 201780043349.5, titled “Method of detecting proteins in...
News 26.08.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and unaudited financial results for the...
News 23.08.2022 Schlieren (Zurich), Switzerland, August 23, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, with completion of enrolment in the PARTNER clinical trial, the first patient treated...
News 23.08.2022 Zurich-Schlieren, Switzerland, August 23, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced the publication of new results comparing its own product Proclarix® and the Prostate Health Index (phi) test from Beckman Coulter. Early detection of prostate cancer is widely performed using screening of total prostate‐specific antigen (PSA)...